The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Quiz|Poll|January 2, 2024
QUIZ: Test Your Psoriasis Knowledge
Author(s)Lauren Buchanan, MA, Managing Editor
Test your knowledge of psoriasis treatment options with our 5-question quiz.
Advertisement
How much do you know about inflammation in psoriasis, biologic methods of action, treatment-emergent adverse events, topical therapies, and biosimilars?
Dermatology Times wants you to test your knowledge of psoriasis treatment options.
Take our 5-question quiz below.
Question 1: What is the hypothesized main contributor to the inflammation seen in psoriasis, according to recent research into the pathophysiology of the disease?
Advertisement
Related to this article
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5